Search Results

Princeton, NJ, January 28, 2026 (Business Wire) -- Taiho Oncology appointed Peter Melnyk as President and Chief Executive Officer, effective immediately, following the retirement of Tim Whitten after 13 years of leadership. Melnyk brings more than three decades of experience in oncology commercialization across pharma, biotech, and medical devices, most recently serving as Chief Commercial Officer at Alpha Tau Medical. His appointment comes as Taiho Oncology builds on recent commercial growth, having expanded from a single product to three marketed therapies across five indications, alongside a growing oncology pipeline. Read full article here .

Berkeley Heights, NJ, January 22, 2026 (Globe Newswire) -- Corxel Pharmaceuticals closed a Series D1 financing of up to $287 million to accelerate development of its cardiometabolic portfolio, led by the oral small-molecule GLP-1 receptor agonist CX11. The proceeds will fund ongoing U.S. Phase 2 studies in obesity and overweight patients, planned global Phase 2 trials in type 2 diabetes, early Phase 3 preparations, and additional programs spanning acute ischemic stroke and hypertension. The round drew strong participation from leading healthcare investors including RTW Investments, SR One, TCG Crossover, RA Capital, HBM Healthcare Investments, and SymBiosis, and will add three new representatives to CORXEL’s board. Read full article here .

Menlo Park, CA, January 12, 2026 (Business Wire) -- Inquis Medical closed a $75 million Series C financing from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation pipeline. The raise follows a pivotal year in which the company transitioned to a commercial-stage organization, expanded regulatory clearance for pulmonary embolism, and published positive pivotal trial data demonstrating effective clot removal with minimized blood loss and no device-related adverse events. Management said the capital will support scaling commercial adoption across the venous thromboembolism market while continuing product innovation. Read full article here .

Billerica, MA, January 8, 2026 (Business Wire) -- Quanterix Corporation appointed Everett Cunningham as President and Chief Executive Officer, effective January 19, 2026, as part of a planned leadership transition. Cunningham joins from Illumina, where he served as Chief Commercial Officer, following earlier commercial leadership roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer. The company said it expects to exceed its full-year 2025 revenue and cash guidance, positioning Quanterix for its next phase of growth under Cunningham’s leadership. Read full article here .

Boston, MA, January 9, 2026 (PRNewswire) -- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a Galway-based medtech company developing next-generation percutaneous vessel closure technology. Vivasure’s PerQseal® Elite system uses a fully bioabsorbable, suture-free patch to close large-bore access sites and has already secured CE Mark approval in Europe, with a U.S. FDA PMA submission completed in 2025. The deal includes €100 million in upfront cash (approximately €52 million net of prior investments and loans) plus up to €85 million in contingent payments tied to sales growth and milestones, funded through Haemonetics’ existing cash reserves. Read full article here .

Melville, NY, January 12, 2026 (Business Wire) -- Henry Schein, Inc. announced the appointment of Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026, at which point he will also join the Board of Directors. Lowery succeeds Stanley M. Bergman, who will step down after 35 years as CEO and continue as Chairman to support a smooth leadership transition. Lowery brings more than 20 years of healthcare distribution and operational leadership experience, most recently serving as Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, where he led above-market growth of the Fisher Scientific distribution business. His background spanning distribution, manufacturing, R&D, marketing, and sales closely aligns with Henry Schein’s integrated business model and its ongoing BOLD+1 strategy, positioning him to guide the company through its next phase of growth and value creation. Read full article here .

Indianapolis, IN, January 7, 2026 (PR Newswire) -- Eli Lilly and Company announced it will acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, expanding its presence in inflammatory-mediated diseases. The deal brings Ventyx’s clinical-stage portfolio of oral small molecules, including NLRP3 inhibitors designed to address chronic inflammation across cardiometabolic, neurodegenerative, and autoimmune conditions. Lilly will pay $14.00 per share, representing a premium of about 62%, with closing expected in the first half of 2026 subject to customary approvals. Read full article here .

Tel Aviv and Boston, MA, December 18, 2025 (Business Wire) -- Syremis Therapeutics debuted with a $165 million Series A financing to develop best-in-class medicines for severe mental health conditions, led by Dexcel Pharma and Third Rock Ventures. The funding will support clinical proof of concept for ST-905, a dual M1/M4 muscarinic agonist already in Phase 1 for schizophrenia, and advance ST-901, a novel NMDA antagonist for major depressive disorder and bipolar depression toward Phase 1 next year. Syremis’ programs, spun out of Clexio Biosciences, aim to address major unmet needs in neuropsychiatric care with therapies rooted in emerging, clinically validated biology. Read full article here .

Boston, MA, December 18, 2025 (Business Wire) -- PureTech Health plc announced that its Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO) and a member of the Board, effective immediately. Lyne had served as interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. His leadership priorities include advancing financing for emerging entities such as Celea Therapeutics following recent regulatory progress, while sharpening strategic focus and operational efficiency. Read full article here .

Paris and Emeryville, CA, December 24, 2025 (Reuters) -- Sanofi announced it will acquire U.S.-based Dynavax Technologies in a deal valued at approximately $2.2 billion, adding an approved adult hepatitis B vaccine and a late-stage shingles candidate to its vaccines pipeline. The transaction, expected to close in Q1 2026, follows recent strategic moves by Sanofi to broaden growth beyond its blockbuster asthma treatment Dupixent, including acquisitions of Vicebio and BluePrint Medicines. Analysts note the deal also positions Sanofi to rebalance its vaccine exposure toward adults amid evolving U.S. policy debates around childhood immunization, with Dynavax shares jumping nearly 40% on the news. Read full article here .

Houston, TX, December 17, 2025 (ACCESS Newswire) -- CNS Pharmaceuticals announced a CEO transition, with industry veteran Rami Levin appointed President and Chief Executive Officer, effective January 1, 2026, following the departure of John Climaco. Levin brings nearly three decades of global leadership experience across oncology, neurology, rare diseases, and cell and gene therapy, including scaling organizations, advancing late-stage programs, and raising capital. The board highlighted Levin’s ability to guide companies through critical inflection points as CNS advances its pipeline, including TPI 287, toward its next phase of growth. Read full article here .

New Brunswick, NJ, December 29, 2025 (PR Newswire) -- Johnson & Johnson has completed its $3.05 billion all-cash acquisition of Halda Therapeutics, adding a differentiated oral oncology platform to its Innovative Medicine portfolio. The deal brings HLD-0915, a once-daily oral prostate cancer therapy designed to overcome resistance mechanisms through Halda’s proprietary RIPTAC™ technology. Beyond prostate cancer, the platform also supports earlier-stage programs across breast, lung, and other solid tumors, with potential applications outside oncology. Read full article here .